Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCTERNAL THERAPEUTICS, INC.

(ONCT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ONCTERNAL THERAPEUTICS, INC.
01/05AFTER HOURS WATCH LIST SCORECARD : Wejo, onct, swim
MT
01/05ONCTERNAL THERAPEUTICS : Corporate Presentation, January 2022
PU
01/04MT NEWSWIRES AFTER HOURS WATCH LIST : Wejo, onct, swim
MT
01/04Oncternal Therapeutics Finalizes Study Design for Late-Stage Mantle Cell Lymphoma Trial..
MT
01/04Oncternal Therapeutics Announces Agreement with U.S. FDA on Phase 3 Registrational Stud..
AQ
01/04Oncternal Therapeutics, Inc. Announces Agreement with U.S. FDA on Phase 3 Registrationa..
CI
2021ONCTERNAL THERAPEUTICS : Lee 2021 ASH Presentation Zilovertamab + Ibrutinib for MCL
PU
2021Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination wi..
AQ
2021Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination wi..
CI
2021Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5..
AQ
2021ONCTERNAL THERAPEUTICS : ONCT-216 - Ravin 2021 CTOS Oral Presentation Slides
PU
2021Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data for ONCT..
AQ
2021Oncternal Therapeutics, Inc. Presents Updated Interim Phase 1/2 Clinical Trial Data for..
CI
2021Oncternal Therapeutics to Present at the 12th Annual Jefferies London Healthcare Confer..
GL
2021ONCTERNAL THERAPEUTICS : Q3 Earnings Snapshot
AQ
2021Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2021Corporate Presentation, November 2021
PU
2021Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results
AQ
2021Oncternal Provides Business Update and Announces Third Quarter 2021 Financial Results -..
PU
2021Oncternal Therapeutics Joins Karolinska Institutet's NextGenNK Competence Center for th..
AQ
2021Oncternal Therapeutics Joins Karolinska Institutet?s NextGenNK Competence Center for th..
CI
2021Oncternal Therapeutics Announces Formation of Cell Therapy Scientific Advisory Board
GL
2021Oncternal Therapeutics, Inc. Announces Board Appointments
CI
2021Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5..
GL
2021Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2021 Financi..
GL
2021ONCTERNAL THERAPEUTICS : AACR-NCI-EORTC Molecular Targets and Cancer Therapuetics Conferen..
PU
2021ONCTERNAL THERAPEUTICS' : Potential Prostate Cancer Drug Shows Anti-Tumor Activity in Prec..
MT
2021ONCTERNAL THERAPEUTICS : Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N..
AQ
2021Oncternal Therapeutics, Inc. Announces Pre-Clinical Data from ONCT-534, an Androgen Rec..
CI
2021ONCTERNAL THERAPEUTICS : Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5..
AQ
2021ONCTERNAL THERAPEUTICS : Celularity Collaborating on Targeted Placental-Derived Cellular T..
MT
2021Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Tar..
GL
2021CELULARITY : and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targ..
AQ
2021Celularity Inc. and Oncternal Therapeutics, Inc. Enter into Research Collaboration to E..
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to S&P Global BMI Index
CI
2021ONCTERNAL THERAPEUTICS : to Participate in September Investor Conferences
AQ
2021ONCTERNAL THERAPEUTICS : Rounds Out Leadership Team with Appointment of Steven Hamburger, ..
AQ
2021Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June..
CI
2021ONCTERNAL THERAPEUTICS : Q2 Earnings Snapshot
AQ
2021Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
GL
2021Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule ..
GL
2021ONCTERNAL THERAPEUTICS : to Participate in the BTIG Virtual Biotechnology Conference
AQ
2021ONCTERNAL THERAPEUTICS : to Provide Business Update and Report Second Quarter 2021 Financi..
AQ
2021Oncternal Therapeutics, Inc. Appoints Pablo Urbaneja as Senior Vice President, Corporat..
CI
2021ONCTERNAL THERAPEUTICS : Corporate Presentation, July 2021
PU
2021ONCTERNAL THERAPEUTICS : Appoints Pablo Urbaneja as Sr. Vice President, Corporate Developm..
AQ
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) dropped from Russell 3000E Growth Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 2000 Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 2000 Dynamic Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 3000 Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell Small Cap Completeness Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell Small Cap Comp Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) dropped from Russell Microcap Growth Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 2000 Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 2500 Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell Microcap Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 2500 Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 3000 Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 3000E Value Index
CI
2021ONCTERNAL THERAPEUTICS, INC.(NASDAQC : ONCT) added to Russell 3000E Index
CI
2021ONCTERNAL THERAPEUTICS : Open Market Sale Agreement (Form 8-K)
PU
2021ONCTERNAL THERAPEUTICS : Ravin 2021 ASCO Slides 11500 Oral Presentation TK216 RR Ewing Sar..
PU
2021Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5..
GL
2021ONCTERNAL THERAPEUTICS : Open Market Sale Agreement (Form 8-K)
PU
2021Oncternal Therapeutics, Inc. Elects Jinzhu Chen as Class II Director
CI
2021Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference
GL
2021Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapse..
GL
2021Oncternal Therapeutics, Inc. Presents Updated Interim Data for TK216 in Patients with R..
CI
2021Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination wit..
GL
2021Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination wit..
CI
2021ONCTERNAL THERAPEUTICS : Names Salim Yazji as Chief Medical Officer
MT
2021Oncternal Therapeutics, Inc. Announces Appointment of Salim Yazji as Chief Medical Offi..
CI
2021Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
GL
2021ONCTERNAL THERAPEUTICS : Q1 Earnings Snapshot
AQ
2021Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results
GL
1  2  3  4Next
Upcoming event on ONCTERNAL THERAPEUTICS, INC.
01/25/22R&D Day